From the recent reports, approximately 18%–20% of breast cancer patients present with human epidermal growth factor receptor 2 (HER2) overexpression, and these patients are featured by rapid tumor progression, short remission period of chemotherapy, higher rate of recurrence, and poor disease-free survival and overall survival (4, 5). This evidence concerns the gene ERBB2 and breast cancer.